Fresenius Stock CINNOBER BOAT

Equities

0OO9

DE0005785604

Healthcare Facilities & Services

Delayed CINNOBER BOAT 5-day change 1st Jan Change
- EUR -.--% Intraday chart for Fresenius -.--% -.--%
Sales 2024 * 22.27B 23.98B Sales 2025 * 23.3B 25.09B Capitalization 16.99B 18.29B
Net income 2024 * 1.38B 1.49B Net income 2025 * 1.73B 1.86B EV / Sales 2024 * 1.32 x
Net Debt 2024 * 12.45B 13.41B Net Debt 2025 * 11.74B 12.64B EV / Sales 2025 * 1.23 x
P/E ratio 2024 *
12.3 x
P/E ratio 2025 *
9.66 x
Employees -
Yield 2024 *
3.13%
Yield 2025 *
3.45%
Free-Float 73.04%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 55 21-04-11
Director of Finance/CFO 44 18-12-31
Compliance Officer - 23-07-17
Members of the board TitleAgeSince
Director/Board Member 69 15-05-19
Chairman 69 19-12-31
Director/Board Member 63 16-05-12
More insiders
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - hospital administration and engineering (64.3%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (35.7%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (72.4%), North America (12.3%), Asia/Pacific (7.3%), Latin America (6.4%) and Africa (1.6%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
30.16 EUR
Average target price
37.19 EUR
Spread / Average Target
+23.32%
Consensus